期刊
VACCINE
卷 27, 期 25-26, 页码 3398-3400出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.01.070
关键词
Cancer; Clinical trial; Immunosuppression; Immunotherapy; Melanoma; Mimotope; T cell; T cell epitope; T cell-directed vaccine; Therapeutic vaccination; Therapeutic vaccine; Tumor immunology
Recent investigations revealed strong immunosuppressive mechanisms in tumors that may block antitumor T cells and be responsible for failures of immunotherapies. Current attempts to overcome this immunosuppression include blockade of co-inhibitory factors on T cells. Reports from the respective trials indicate that the strategy can improve efficacy of therapeutic vaccination, but at the cost of severe inflammatory and autoimmune reactions. We tried to circumvent tumor-associated immunosuppression by mimotope vaccination to broaden reactive anti-tumor T cell repertoires to include T cells that have not been rendered anergic by the tumor. Initial clinical observations Suggest that this strategy bears considerable promise. (c) 2009 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据